|
業務類別
|
Biotechnology |
|
業務概覽
|
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology. |
| 公司地址
| 5005 McConnell Avenue, Los Angeles, CA, USA, 90066 |
| 電話號碼
| +1 310 665-2928 |
| 傳真號碼
| +1 310 665-2963 |
| 公司網頁
| https://www.armatapharma.com |
| 員工數量
| 61 |
| Mr. David D. House |
Senior Vice President, Finance and Principal Financial Officer |
美元 360.50K |
27/04/2026 |
| Dr. Deborah L. Birx, M.D. |
Chief Executive Officer and Director |
美元 562.38K |
27/04/2026 |
| Mr. Pierre Kyme |
Chief Business Officer |
美元 412.00K |
27/04/2026 |
|
|
| Mr. Daniel B. Gilmer, PhD |
Independent Director |
27/04/2026 |
| Mr. Jules Haimovitz |
Independent Director |
27/04/2026 |
| Dr. Joseph M. Patti,PhD |
Independent Director |
27/04/2026 |
| Dr. Odysseas D. Kostas, M.D. |
Independent Director |
27/04/2026 |
| Dr. Deborah L. Birx, M.D. |
Chief Executive Officer and Director |
27/04/2026 |
| Dr. Sarah J. Schlesinger, M.D. |
Independent Director |
27/04/2026 |
| Ms. Robin C. Kramer |
Chairman of the Board |
27/04/2026 |
| Dr. Todd C. Peterson, PhD |
Independent Director |
27/04/2026 |
|
|
|
|
